In recent years, the medical approach to weight loss has undergone a paradigm shift, driven largely by a class of medications known as GLP-1 receptor agonists.
For decades, the standard medical advice for weight loss was simply “eat less and move more.” However, modern endocrinology recognizes that obesity is a complex, chronic metabolic disease, heavily influenced by hormones. GLP-1 medications directly address this hormonal imbalance.
Here is a simplified look at the fascinating science behind how these treatments work.
What is GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1. It is a naturally occurring incretin hormone produced in the intestines when you eat a meal.
In a healthy metabolic system, GLP-1 acts as a powerful messenger, performing several critical functions:
- Insulin Secretion: It signals the pancreas to release insulin, which helps move glucose from your blood into your cells for energy.
- Glucagon Suppression: It stops the liver from releasing too much stored sugar into the bloodstream.
- Gastric Emptying: It slows down the rate at which food leaves your stomach, keeping you physically full for longer.
- Satiety Signaling: It travels to the hypothalamus (the appetite control center of the brain) and signals that you are full, suppressing the desire to eat.
In many individuals struggling with obesity or insulin resistance, the natural GLP-1 response is blunted or dysfunctional.
How the Medications Work
Medications like Wegovy (semaglutide) are synthetically engineered versions of your body’s natural GLP-1 hormone.
However, natural GLP-1 is degraded by an enzyme in your body (DPP-4) in less than two minutes. The brilliant scientific breakthrough behind medications like Wegovy was modifying the molecular structure of the hormone so that it resists this degradation. As a result, instead of lasting for two minutes, a single injection of Wegovy remains active in your body for an entire week.
By providing a steady, continuous stream of this “fullness hormone,” the medication essentially rewires your brain’s relationship with food. It quiets what many patients describe as “food noise”—the constant, intrusive thoughts about eating.
The Next Step: Dual Agonists
The science has recently advanced even further with the introduction of Mounjaro (tirzepatide). Mounjaro is a “dual-agonist.”
Alongside GLP-1, it also mimics a second hormone called GIP (Glucose-Dependent Insulinotropic Polypeptide). GIP works synergistically with GLP-1 to enhance insulin sensitivity and further regulate lipid (fat) metabolism. This dual-action approach is why Mounjaro has demonstrated even greater average weight loss results in clinical trials than single GLP-1 agonists.
A Medical Treatment, Not a Cosmetic Fix
Understanding the science highlights why these medications are not “cheating.” They are correcting an underlying physiological imbalance. Just as a patient with hypothyroidism requires thyroid hormone replacement, many patients with obesity require incretin hormone therapy to effectively manage their metabolism and appetite.
At Prescriptly, we believe in empowering our patients with knowledge. When you understand how these treatments work on a cellular level, you are better equipped to partner with them through healthy diet and exercise to achieve lasting, life-changing results.